Description

BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth[1].—–C74H92ClN17O13—-[1]Bogden AE,et al. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res. 1990 May 1;50(9):2646-50.|[2]Ban E, Crumeyrolle-Arias M, Latouche J, Leblanc P, Heurtier JF, Drieu K, Fillion G, Haour F. GnRH receptors in rat brain, pituitary and testis; modulation following surgical and gonadotropin-releasing hormone agonist-induced castration. Mol Cell Endocrinol. 1990 Mar 26;70(1):99-107.–106881-54-3–1463.08—-C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CC2=CC=CC=C2)NC([C@@H](CCCNC(N)=N)NC([C@H](CC3=CC=C(O)C=C3)NC([C@H](CO)NC([C@@H](CC4=CC=CC=C4)NC([C@@H](CC5=CC=C(Cl)C=C5)NC([C@@H](CC6=CC=C7C=CC=CC7=C6)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O–Cancer–10 mM in DMSO–GnRH Receptor—-GPCR/G Protein–Peptides